p16/p53 gene therapy - DeveloGen

Drug Profile

p16/p53 gene therapy - DeveloGen

Latest Information Update: 25 Jul 2001

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator DeveloGen
  • Class
  • Mechanism of Action Cyclin-dependent kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Liver cancer

Most Recent Events

  • 25 Jul 2001 Discontinued-Preclinical for Liver cancer in Germany (Unknown route)
  • 27 Nov 2000 HepaVec has been acquired by DeveloGen
  • 07 Dec 1999 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top